TRAVERE THERAPEUTICS INC - NOTE 2.500% 9/1 Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2018 to Q3 2025

Type / Class
Debt / NOTE 2.500% 9/1
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.500% 9/1 across Reporting Periods

Period Principal Value Change Price (% of par) (Median) Investors
2025 Q3 $0 $0 -$64,873,603 0
2025 Q2 $57,640,000 $64,873,603 98.86% 8
2025 Q1 $57,640,000 $64,618,581 +$1,020,671 98.67% 8
2024 Q4 $56,600,000 $63,802,890 +$213,600 98.85% 8
2024 Q3 $66,208,000 $63,325,088 -$512,804 95.52% 5
2024 Q2 $67,255,000 $58,773,494 87.03% 6
2024 Q1 $67,310,800 $59,949,400 +$122,845 87.6% 7
2023 Q4 $67,755,000 $57,624,003 84.75% 7
2023 Q3 $67,755,000 $58,238,845 85.06% 7
2023 Q2 $67,755,000 $60,878,048 -$11,272 88.84% 7
2023 Q1 $67,746,000 $65,086,027 +$234,419 95.2% 6
2022 Q4 $67,746,000 $62,476,012 -$13,243,908 92.04% 8
2022 Q3 $30,008,000 $30,205,845 -$3,982,998 100.67% 10
2022 Q2 $34,008,000 $33,596,000 -$34,568,575 99.1% 11
2022 Q1 $67,590,000 $70,167,000 -$194,402,579 103.76% 22
2021 Q4 $245,979,899 $269,836,182 +$10,411,904 109.45% 33
2021 Q3 $237,624,845 $238,892,012 +$41,243,362 100.67% 32
2021 Q2 $202,164,345 $171,528,963 -$1,715,628 85.06% 32
2021 Q1 $200,793,014 $204,817,314 -$29,235,582 102.1% 30
2020 Q4 $228,513,000 $232,919,000 +$4,189,127 101.47% 29
2020 Q3 $231,467,000 $197,057,000 +$10,789,044 85.49% 33
2020 Q2 $208,899,973 $173,045,653 -$9,513,086 82.47% 34
2020 Q1 $269,379,000 $206,809,000 +$36,432,632 78.4% 37
2019 Q4 $221,851,979 $173,716,000 +$399,475 77.77% 31
2019 Q3 $221,348,000 $166,426,000 +$82,162 74.46% 30
2019 Q2 $219,498,750 $197,556,831 +$2,529,427 90.0% 35
2019 Q1 $215,705,000 $202,722,815 +$3,297,424 93.47% 32
2018 Q4 $212,377,000 $190,246,096 -$21,147,111 89.6% 31
2018 Q3 $222,564,000 $229,471,000 +$229,471,000 102.5% 29